PMID: 15247625Jul 13, 2004Paper

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

Pharmacogenetics
Dyfrig A HughesMunir Pirmohamed

Abstract

Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients. HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians. Our aim was to confirm the presence of this genetic factor in our patients, and to determine whether genotyping for HLA B*5701 would be a cost-effective use of healthcare resources. Patients with and without abacavir hypersensitivity were identified from a UK HIV clinic. Patients were genotyped for HLA B*5701, and pooled data used for calculation of test characteristics. The cost-effectiveness analysis incorporated the cost of testing, cost of treating abacavir hypersensitivity, and the cost and selection of alternative antiretroviral regimens. A probabilistic decision analytic model (comparing testing versus no testing) was formulated and Monte Carlo simulations performed. Of the abacavir hypersensitive patients, six (46%) were HLA B*5701 positive, compared to five (10%) of the non-hypersensitive patients (odds ratio 7.9 [95% confidence intervals 1.5-41.4], P = 0.006). Pooling of our data on HLA B*5701 with published data resulted in a pooled odds ratio of 29 (95% CI 6.4-132.3; P < 0.0001...Continue Reading

References

Jan 1, 1992·Scandinavian Journal of Rheumatology. Supplement·J F Fries
Feb 7, 2001·BMJ : British Medical Journal·C R WolfR L Smith
Jun 24, 2000·Nature·A D Roses
Mar 20, 2001·JAMA : the Journal of the American Medical Association·S StaszewskiUNKNOWN CNAAB3005 International Study Team
Jun 8, 2001·Trends in Pharmacological Sciences·M Pirmohamed, B K Park
Apr 12, 2002·Lancet·Seth HetheringtonAllen D Roses
May 23, 2002·Clinical Therapeutics·William SymondsSeth Hetherington
Jul 18, 2002·Nature Reviews. Drug Discovery·Allen D Roses
Dec 5, 2002·Clinical Therapeutics·Patrick G Clay
Feb 20, 2003·American Journal of Human Genetics·Quanhe YangW Dana Flanders
Apr 30, 2003·Pharmacogenomics·Kathryn A PhillipsJulie Sakowski
Jun 17, 2003·PharmacoEconomics·Rosa Rodríguez-MonguióJoan Rovira
Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·I Martinelli
Sep 12, 2003·The New England Journal of Medicine·Esteban MartínezUNKNOWN Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team
Oct 2, 2003·The Annals of Pharmacotherapy·Hélène PeyriereJacques Reynes

❮ Previous
Next ❯

Citations

Jan 29, 2008·European Journal of Clinical Pharmacology·Jürgen Brockmöller, Mladen V Tzvetkov
Jun 29, 2010·European Journal of Clinical Pharmacology·Guillermo GervasiniJuan Antonio Carrillo
Apr 15, 2005·Mutation Research·Thierry DervieuxBruce Neri
Aug 2, 2005·Nature Reviews. Drug Discovery·Julia KirchheinerJürgen Brockmöller
Feb 8, 2006·The Pharmacogenomics Journal·S Rodríguez-NóvoaV Soriano
Sep 14, 2006·The Pharmacogenomics Journal·L L WarrenUNKNOWN CNA30027 and CNA30032 study teams
Mar 19, 2008·The Pharmacogenomics Journal·D F HeitjanC Lerman
Feb 8, 2008·The New England Journal of Medicine·Magnus Ingelman-Sundberg
Mar 25, 2011·The New England Journal of Medicine·Mark McCormackMunir Pirmohamed
Oct 15, 2010·The New England Journal of Medicine·Charles N Rotimi, Lynn B Jorde
May 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Celia K S ChuiP Richard Harrigan
Jan 11, 2008·AIDS Research and Human Retroviruses·Sonia Rodríguez-NóvoaVincent Soriano
Jul 4, 2006·AIDS·Joanne SteklerAnn C Collier
Sep 27, 2006·Pharmacogenetics and Genomics·Andrew OwenDavid J Back
Nov 1, 2005·Current Opinion in Infectious Diseases·Marta BoffitoAndrew Owen
Dec 18, 2010·The Pediatric Infectious Disease Journal·Patricia Nahirya-NtegeUNKNOWN ARROW Trial Team
Dec 6, 2012·AIDS·James D WilkinsonUNKNOWN Pediatric HIVAIDS Cohort Study (PHACS)
Jan 15, 2008·Current Opinion in Infectious Diseases·Elizabeth J Phillips, Simon A Mallal
Nov 14, 2006·Sexually Transmitted Infections·S T Sadiq, M Pakianathan
Sep 22, 2007·Annual Review of Pharmacology and Toxicology·A Telenti, U M Zanger
Jan 31, 2013·Genome Medicine·Ann K Daly
Dec 15, 2010·PLoS Currents·Joseph D MaGrace M Kuo
Jan 5, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kristine R CrewsJames M Hoffman
Oct 13, 2010·PharmacoEconomics·William B WongDavid L Veenstra
Jul 1, 2011·Indian Journal of Dermatology·Kisalay GhoshJayoti Nandi
Aug 23, 2011·Ghana Medical Journal·Jairo A Garcia A, Lewis R Roberts
Aug 28, 2012·Pharmacogenomics·Rebecca PavlosElizabeth Phillips
Dec 23, 2006·Pharmacogenomics·Thierry Dervieux, Mohan V Bala
Mar 29, 2008·Pharmacogenomics·Hiroyuki GatanagaShinichi Oka
Dec 3, 2010·Pharmacogenomics·Mathieu BeaulieuJean Lachaine
Mar 20, 2010·Pharmacogenomics·Laurent Becquemont
Jun 7, 2006·Pharmacogenomics·Julie FoxAlan Winston
Mar 7, 2006·Pharmacogenomics·Jeantine E LunshofDavid Gurwitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.